Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06412965 · ClinicalTrials.gov registry record
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 528
- Enrollment target
NCT06412965: Completed study, sponsored by Pfizer.
NCT06412965 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 528 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06412965 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 528 participants
- Enrollment target
Study Summary
This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute treatment for migraine attacks.
Primary Outcome
Physicians responded as "Yes" or "No" if participants failed to achieve pain freedom within 2 hours post dose. In this outcome measure, number of participants were reported according to physicians' responses. Participant who failed to achieve pain freedom at 2 hours post dose on more than half of the occasion were reported in this outcome measure.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 528 participants |
| Start Date | 2024-01-02 |
| Est. Completion | 2024-01-03 |
What the finished NCT06412965 record still lists
NCT06412965 is an observational study that tracks outcomes without assigning an intervention. The registered 528 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06412965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06412965 about?
NCT06412965 is a clinical study titled "Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine". This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute treatment for migraine attacks.
What is the current status of trial NCT06412965?
This trial is currently completed. The enrollment target is 528 participants. The study started on 2024-01-02. Estimated completion is 2024-01-03.
Who is sponsoring clinical trial NCT06412965?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373017 · 528 participants · NA
Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors
- NCT05634252 · 528 participants · Phase 3
Undergraduate Skin Cancer Prevention Trial
- NCT06383273 · 528 participants · Phase 3
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
- NCT06470243 · 528 participants · Phase 3
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI